Skip to content


  • Letter to the Editor
  • Open Access

Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells

  • 1, 2,
  • 1,
  • 2,
  • 2,
  • 2,
  • 2,
  • 2,
  • 2, 3Email author and
  • 2, 3Email author
Journal of Hematology & Oncology20158:2

  • Received: 10 December 2014
  • Accepted: 18 December 2014
  • Published:


High rates of aerobic glycolysis represent a key mechanism by which endometrial cancer cells consume glucose as its primary energy source. The up-regulated glycolytic pathway is a common therapeutic target whose inhibition has implications for anti-tumor activity in cancer cells. The present study was aimed at evaluating the potential of a novel lactate dehydrogenase (LDH) inhibitor, Galloflavin, as a therapeutic agent for endometrial cancer. Our results revealed that Galloflavin effectively inhibited cell growth in endometrial cancer cell lines and primary cultures of human endometrial cancer through its involvement in multiple signaling pathways that regulate metabolism, cell cycle, apoptosis, cell stress and metastasis.


  • Endometrial Cancer
  • LDH
  • Galloflavin
  • Glycolysis

To the Editor

Galloflavin (GF), which is synthesized from gallic acid, is a new lactate dehydrogenase inhibitor that inhibits both the A and B isoforms of LDH [1]. By serving as a competitive inhibitor with NADH for LDH, GF has been shown to disrupt aerobic glycolysis and decrease cell viability effectively across many cancer cell types, including breast, colon and liver cancers as well as Burkitt lymphoma [2-4]. To investigate the effect of GF on endometrial cancer cell growth, we utilized the Ishikawa and ECC-1 cells exhibiting high rates of glycolysis to identify the potential of GF. GF significantly reduced LDHA activity, inhibited cell proliferation and reduced colony formation in a dose dependent manner (Figure 1, Additional file 1). The IC50 values for the ECC-1 and Ishikawa cells were 25 uM and 43 uM after 72 hours of treatment, respectively. We next confirmed that GF was responsible for the activation of the mitochondrial apoptosis pathway, accompanied by an increase in cleaved caspase3 and a decrease in MCL-1 and BCL-2 protein expression (Additional file 2: Figure S1). Cell cycle analysis showed minimal G1 phase arrest in the ECC-1 cells and G2 arrest in Ishikawa cells after 24 hours of treatment (Additional file 3: Figure S2), thus, suggesting that GF induces cell cycle changes by altering different checkpoints in different endometrial cancer cells. After treatment with GF for 24 hours, both cell lines had a reduced ability to adhere to laminin-1 as well as decreased migratory capacity as evaluated by a transwell assay. In addition, E–cadherin increased while Slug proteins decreased after treatment with GF (Additional file 4: Figure S3). GF was also shown to increase reactive oxygen species (ROS) and mitochondrial DNA damage after 24 hours of treatment (Additional file 5: Figure S4), indicating that an increase in ROS production and mitochondrial DNA damage might also be involved in the anti-tumorigenic effects of GF in endometrial cancer cells.
Figure 1
Figure 1

Galloflavin inhibited cell proliferation in the ECC-1 and Ishikawa cells. The ECC-1 and Ishikawa cell lines were cultured in 96-well plates for 24 hours and treated with GF at the indicated doses for 72 hours. Cell proliferation was assessed with MTT assay (A). The cells were cultured in 6 well plates for 24 hours, treated with GF for 48 hours and then cultured for an additional 10 days. Colony formation assay was assessed (B, C). The effect of GF on LDHA activity level was examined using a LDHA activity assay kit (D). GF decreased LDHA activity in the endometrial cancer cells after 16 hours of treatment. (* < 0.05).

Cancer cells maintain a significant level of mitochondrial oxidative phosphorylation (OXPHOS) capacity to rapidly switch from glycolysis to OXPHOS during carcinogenesis and cell energy stress [5,6]. The point of balance between glycolysis and mitochondrial OXPHOS fluctuates depending on changes in the cancer cells microenvironment. Inhibition of LDHA activity by GF resulted in a decreased rate of glucose uptake and ATP production, with subsequent increased pyruvate dehydrogenase (PDH) protein expression and production of pyruvate (Additional file 6: Figure S5). These findings confirm a direct effect of GF on the glucose metabolism by impairing cytosolic glycolysis in the endometrial cancer cells. Since glycolysis and OXPHOS are tightly coupled processes [7], we noted that GF increased glutaminase protein expression, and enhanced Krebs cycle activity, by increasing the production of malate, another Krebs cycle intermediate, after 16 hours of treatment (Additional file 7: Figure S6). GF was effective in inhibition of cell proliferation in 6 of the 8 primary cultures of endometrial cancer with IC50 values ranging from 20-53 uM. A linear regression model showed the level of LDHA protein but not c-Myc was related to the sensitivity to GF in primary cultures and endometrial cancer cell lines (Figure 2). Moreover, we found that GF decreased c-Myc expression in a dose-dependent manner after 24 hours of treatment. Given that c-Myc transcriptionally induces expression and activity of LDHA [8], the inhibition of c-Myc by JQ1 (a c-Myc inhibitor) synergistically increased the inhibitory effects of GF at different concentrations in GF-sensitive and GF-resistant cells (Additional file 7: Figure S6). These results suggest a causal link between GF treatment and down-regulation of c-Myc expression in endometrial cancer cells (Additional file 8: Figure S7). In conclusion, our study indicated that targeted inhibition of LDH by GF has promising anti-tumor activity in endometrial cancer cell lines and primary cultures of endometrial cancer cells. We believe our present study demonstrates that inhibition of LDH by GF decreases cell proliferation, invasion, and glycolytic metabolism while promoting cell stress and apoptosis in endometrial cancer cells. These findings provide a molecular basis for the use of LDH inhibitors in the treatment of endometrial cancer.
Figure 2
Figure 2

Galloflavin inhibited cell proliferation in primary cultures of endometrial cancer. Eight primary cell cultures of endometrial cancer were cultured in 96 well plates and treated with GF as indicated doses for 72 hours. Cell proliferation was assessed by MTT assay (A). LDHA protein expression in the primary cell cultures was detected by Western blotting (B). Eight established endometrial cancer and ovarian cancer cell lines were cultured in 96 well plates, and treated with GF for 72 hours. Cell proliferation was assessed by MTT assay (C). LDHA and c-Myc protein expression in the eight cell lines was detected by Western blotting (D). The relationship of LDHA and c-Myc protein expression and cell response to GF was assessed by Pearson correlation. The results showed a significant correlation between LDHA expression and cell growth inhibition by GF (Pearson r =0.77026; p = 0.0005; n = 16) (E). There was no significant correlation between c-Myc protein expression and cell sensitivity to GF (F) (* < 0.05).




This work was generously supported by NIH/NCI 1K23CA143154-01A1 and the Steelman fund.

Authors’ Affiliations

Department of Gynecologic Oncology, ShanDong Cancer Hospital & Cancer Institute, Jinan, 250117, P.R China
Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, CB# 7572, Physicians Office Building Rm# B105, Chapel Hill, NC 27599, USA
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA


  1. Manerba M, Vettraino M, Fiume L, Di Stefano G, Sartini A, Giacomini E, et al. Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase. Chem Med Chem. 2012;7(2):311–7.PubMedView ArticleGoogle Scholar
  2. Vettraino M, Manerba M, Govoni M, Di Stefano G. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1. Anticancer Drugs. 2013;24(8):862–70.PubMedView ArticleGoogle Scholar
  3. Fiume L, Vettraino M, Carnicelli D, Arfilli V, Di Stefano G, Brigotti M. Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells. Biochem Biophys Res Commun. 2013;430(2):466–9.PubMedView ArticleGoogle Scholar
  4. Farabegoli F, Vettraino M, Manerba M, Fiume L, Roberti M, Di Stefano G. Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. Eur J Pharm Sci. 2012;47(4):729–38.PubMedView ArticleGoogle Scholar
  5. Billiard J, Dennison JB, Briand J, Annan RS, Chai D, Colón M, et al. Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer Metab. 2013;1(1):19.PubMed CentralPubMedView ArticleGoogle Scholar
  6. Antico Arciuch VG, Russo MA, Kang KS, Di Cristofano A. Inhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells. Cancer Res. 2013;73(17):5459–72.PubMed CentralPubMedView ArticleGoogle Scholar
  7. Dang CV, Hamaker M, Sun P, Le A, Gao P. Therapeutic targeting of cancer cell metabolism. J Mol Med. 2011;89:205–12.PubMed CentralPubMedView ArticleGoogle Scholar
  8. Nilsson LM, Forshell TZ, Rimpi S, Kreutzer C, Pretsch W, Bornkamm GW, et al. Mouse genetics suggests cell-context dependency for Myc-regulated metabolic enzymes during tumorigenesis. PLoS Genet. 2012;8(3):e1002573.PubMed CentralPubMedView ArticleGoogle Scholar


© Han et al.; licensee Biomed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.